ADC Therapeutics presents exatecan-based ADC platform at virtual investor event

ADC Therapeutics SA

CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.
Agenda includes business update, research strategy, platform, and lead candidates.
Presentation made available on April 9, 2024, with live Q&A session to follow.
No financial results or material non-public information disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.